Literature DB >> 29664340

Pancreatic Ductal Adenocarcinoma: Rim Enhancement at MR Imaging Predicts Prognosis after Curative Resection.

Sunyoung Lee1, Seong Hyun Kim1, Hyung Kyu Park1, Kee Taek Jang1, Jeong Ah Hwang1, Seonwoo Kim1.   

Abstract

Purpose To identify features at preoperative magnetic resonance (MR) imaging that could predict favorable prognosis after curative resection of pancreatic ductal adenocarcinoma (PDAC). Materials and Methods From January 2009 to December 2014, this retrospective study included 143 patients with surgically resected (ie, R0) PDAC who underwent preoperative MR imaging within 1 month before surgery. Clinical-pathologic and MR imaging findings for predicting disease-free survival (DFS) and overall survival (OS) were identified by using a Cox proportional hazards model. Important MR imaging features were compared with clinical-pathologic findings. Results Tumor size at histopathologic analysis was associated with both DFS and OS (hazard ratio per centimeter, 1.37; 95% confidence interval: 1.15, 1.63; P < .001 and hazard ratio, 1.44; 95% confidence interval: 1.20, 1.73; P < .001, respectively). Rim enhancement at dynamic contrast material-enhanced MR imaging was associated with significantly worse DFS and OS (hazard ratio, 1.72; 95% confidence interval: 1.05, 2.82; P = .030 and hazard ratio, 2.27; 95% confidence interval: 1.39, 3.69; P = .001, respectively). Diffusion-weighted imaging parameters, including diffusion restriction and apparent diffusion coefficient value, did not predict DFS or OS after resection of PDAC (all P > .05). Rim-enhancing lesions had more aggressive histologic tumor grades, less frequent remaining acini, and more frequent necrosis within the tumor compared with non-rim-enhancing pancreatic lesions (P = .002, P = .008, and P < .001, respectively). Conclusion Greater tumor size and rim enhancement were associated with lower DFS and OS rates after attempted curative resection of PDAC. © RSNA, 2018 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2018        PMID: 29664340     DOI: 10.1148/radiol.2018172331

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

Review 1.  White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.

Authors:  Naveen M Kulkarni; Lorenzo Mannelli; Marc Zins; Priya R Bhosale; Hina Arif-Tiwari; Olga R Brook; Elizabeth M Hecht; Fay Kastrinos; Zhen Jane Wang; Erik V Soloff; Parag P Tolat; Guillermo Sangster; Jason Fleming; Eric P Tamm; Avinash R Kambadakone
Journal:  Abdom Radiol (NY)       Date:  2020-03

2.  Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).

Authors:  Ken-Ichi Okada; Manabu Kawai; Seiko Hirono; Fumiyoshi Kojima; Kensuke Tanioka; Masaki Terada; Motoki Miyazawa; Yuji Kitahata; Yoshifumi Iwahashi; Masaki Ueno; Shinya Hayami; Shin-Ichi Murata; Toshio Shimokawa; Hiroki Yamaue
Journal:  Langenbecks Arch Surg       Date:  2020-01-28       Impact factor: 3.445

3.  A predictive model for recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma (PDAC) by using preoperative clinical data and CT characteristics.

Authors:  Ningzi Tian; Dong Wu; Lei Zhu; Mengsu Zeng; Jianke Li; Xiaolin Wang
Journal:  BMC Med Imaging       Date:  2022-07-03       Impact factor: 2.795

4.  Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy.

Authors:  Seung-Seob Kim; Sunyoung Lee; Hee Seung Lee; Seungmin Bang; Mi-Suk Park
Journal:  Abdom Radiol (NY)       Date:  2020-08-03

5.  Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study.

Authors:  Mohamed Zaid; Lauren Widmann; Annie Dai; Kevin Sun; Jie Zhang; Jun Zhao; Mark W Hurd; Gauri R Varadhachary; Robert A Wolff; Anirban Maitra; Matthew H G Katz; Joseph M Herman; Huamin Wang; Michael V Knopp; Terence M Williams; Priya Bhosale; Eric P Tamm; Eugene J Koay
Journal:  Cancers (Basel)       Date:  2020-12-05       Impact factor: 6.639

Review 6.  The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma.

Authors:  Hyungjin Rhee; Mi Suk Park
Journal:  Korean J Radiol       Date:  2020-08-28       Impact factor: 3.500

7.  Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma.

Authors:  Tongtong Zhou; Li Tan; Yang Gui; Jing Zhang; Xueqi Chen; Menghua Dai; Mengsu Xiao; Qing Zhang; Xiaoyan Chang; Qun Xu; Chunmei Bai; Yuejuan Cheng; Qiang Xu; Xue Wang; Hua Meng; Wanying Jia; Ke Lv; Yuxin Jiang
Journal:  Cancer Manag Res       Date:  2021-08-31       Impact factor: 3.989

8.  Prediction of overall survival in patients with pancreatic ductal adenocarcinoma: histogram analysis of ADC value and correlation with pathological intratumoral necrosis.

Authors:  Yoshifumi Noda; Hiroyuki Tomita; Takuma Ishihara; Yoshiki Tsuboi; Nobuyuki Kawai; Masaya Kawaguchi; Tetsuro Kaga; Fuminori Hyodo; Akira Hara; Avinash R Kambadakone; Masayuki Matsuo
Journal:  BMC Med Imaging       Date:  2022-02-08       Impact factor: 1.930

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.